Search

Your search keyword '"Michael Cerezo"' showing total 11 results
Start Over Author "Michael Cerezo" Topic humans
11 results on '"Michael Cerezo"'

1. The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance

Author

Caroline Robert, Shensi Shen, Lunxu Liu, and Michael Cerezo

Subjects
Cancer Research, Tumor microenvironment, medicine.medical_treatment, Cancer, Translation (biology), Immunotherapy, Biology, medicine.disease, Immune checkpoint, Immune system, Antineoplastic Agents, Immunological, Oncology, Cancer immunotherapy, Drug Resistance, Neoplasm, Neoplasms, Protein Biosynthesis, Translational regulation, medicine, Cancer research, Tumor Microenvironment, Animals, Humans, Tumor Escape, RNA, Messenger
Abstract

Tremendous advances have been made in cancer immunotherapy over the last decade. Among the different steps of gene expression, translation of mRNA is emerging as an essential player in both cancer and immunity. Changes in mRNA translation are both rapid and adaptive, and translational reprogramming is known to be necessary for sustaining cancer cell proliferation. However, the role of mRNA translation in shaping an immune microenvironment permissive to tumors has not been extensively studied. Recent studies on immunotherapy approaches have indicated critical roles of mRNA translation in regulating the expression of immune checkpoint proteins, tuning the secretion of inflammation-associated factors, modulating the differentiation of immune cells in the tumor microenvironment, and promoting cancer resistance to immunotherapies. Careful consideration of the role of mRNA translation in the tumor-immune ecosystem could suggest more effective therapeutic strategies and may eventually change the current paradigm of cancer immunotherapy. In this review, we discuss recent advances in understanding the relationship between mRNA translation and tumor-associated immunity, the potential mechanisms of immunotherapy resistance in cancers linked to translational reprogramming, and therapeutic perspectives and potential challenges of modulating translational regulation in cancer immunotherapy.

Published
2021

2. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma

Author

Alain Eychène, Laurent Désaubry, Michael Cerezo, Alexander M.M. Eggermont, Jean-Yves Scoazec, Stéphan Vagner, Nahum Sonenberg, Isabelle Girault, Sandrine Agoussi, Sylvain Martineau, Julien Adam, C. Libenciuc, Shensi Shen, Emilie Routier, Ramdane Guemiri, Charlène Estrada, Hélène Malka-Mahieu, Caroline Robert, Séverine Roy, Delphine Allard, Sabine Druillennec, Caroline Welsch, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Signalisation normale et pathologique de l'embryon aux thérapies innovantes des cancers, Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Régulation de la réponse immune, infection VIH-1 et autoimmunité, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Stress génotoxiques et cancer, Université Paris-Sud - Paris 11 (UP11)-Institut Curie [Paris]-Centre National de la Recherche Scientifique (CNRS), Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Substances naturelles/chimie moléculaire, Université Louis Pasteur - Strasbourg I-Ecole européenne de chimie, polymères et matériaux [Strasbourg]-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), Department of Biochemistry, Hôpital Lapeyronie, Département de biologie et pathologie médicales [Gustave Roussy], and Service de dermatologie

Subjects
0301 basic medicine, drug effects, immunology, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Aucun, [SDV.CAN]Life Sciences [q-bio]/Cancer, antagonists & inhibitors, genetics, therapeutic use, General Biochemistry, Genetics and Molecular Biology, B7-H1 Antigen, 03 medical and health sciences, Interferon-gamma, Mice, Eukaryotic translation, Downregulation and upregulation, Cell Line, Tumor, medicine, Animals, Humans, STAT1, Transcription factor, Melanoma, ComputingMilieux_MISCELLANEOUS, Messenger RNA, biology, Chemistry, General Medicine, Immunotherapy, 3. Good health, Gene Expression Regulation, Neoplastic, 030104 developmental biology, STAT1 Transcription Factor, Eukaryotic Initiation Factor-4F, eIF4A, Protein Biosynthesis, biology.protein, STAT protein, Cancer research, Tumor Escape, pathology, therapy, Signal Transduction
Abstract

Preventing the immune escape of tumor cells by blocking inhibitory checkpoints, such as the interaction between programmed death ligand-1 (PD-L1) and programmed death-1 (PD-1) receptor, is a powerful anticancer approach. However, many patients do not respond to checkpoint blockade. Tumor PD-L1 expression is a potential efficacy biomarker, but the complex mechanisms underlying its regulation are not completely understood. Here, we show that the eukaryotic translation initiation complex, eIF4F, which binds the 5' cap of mRNAs, regulates the surface expression of interferon-γ-induced PD-L1 on cancer cells by regulating translation of the mRNA encoding the signal transducer and activator of transcription 1 (STAT1) transcription factor. eIF4F complex formation correlates with response to immunotherapy in human melanoma. Pharmacological inhibition of eIF4A, the RNA helicase component of eIF4F, elicits powerful antitumor immune-mediated effects via PD-L1 downregulation. Thus, eIF4A inhibitors, in development as anticancer drugs, may also act as cancer immunotherapies. journal article research support, non-u.s. gov't 2018 12 2018 10 29 imported

Published
2018
Full Text
View/download PDF

3. Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

Author

Mickaël Ohanna, Philippe Bahadoran, Sophie Tartare-Deckert, Mélanie Tichet, Patricia Abbe, Stéphane Rocchi, Corine Bertolotto, Michael Cerezo, Robert Ballotti, Abdelali Lehraiki, Florian Rouaud, Damien Giacchero, Maryline Allegra, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), BERTOLOTTO-BALLOTTI, BERTOLOTTO-BALLOTTI, Université Nice Sophia Antipolis (1965 - 2019) (UNS), and COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)

Subjects
Cancer Research, medicine.medical_specialty, Epithelial-Mesenchymal Transition, endocrine system diseases, [SDV.CAN]Life Sciences [q-bio]/Cancer, AMP-Activated Protein Kinases, Metastasis, Mice, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cell Movement, Cell Line, Tumor, Internal medicine, medicine, Animals, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Melanoma, 030304 developmental biology, 0303 health sciences, Chemistry, Metalloendopeptidases, AMPK, Cell migration, medicine.disease, Metformin, Extravasation, 3. Good health, Enzyme Activation, Disease Models, Animal, Endocrinology, Oncology, Cell culture, 030220 oncology & carcinogenesis, Cancer cell, Cancer research, Female, Tumor Suppressor Protein p53, medicine.drug
Abstract

Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells. In this report, we investigated the effect of metformin on melanoma invasion and metastasis development. Using different in vitro approaches, we found that metformin inhibits cell invasion without affecting cell migration and independently of antiproliferation action. This inhibition is correlated with modulation of expression of proteins involved in epithelial–mesenchymal transition such as Slug, Snail, SPARC, fibronectin, and N-cadherin and with inhibition of MMP-2 and MMP-9 activation. Furthermore, our data indicate that this process is dependent on activation of AMPK and tumor suppressor protein p53. Finally, we showed that metformin inhibits melanoma metastasis development in mice using extravasation and metastasis models. The presented data reinforce the fact that metformin might be a good candidate for clinical trial in melanoma treatment. Mol Cancer Ther; 12(8); 1605–15. ©2013 AACR.

Published
2013
Full Text
View/download PDF

4. Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells

Author

Emilie Jaune, Patricia Abbe, Antoine Millet, Magali Plaisant, Michael Cerezo, Cyril Ronco, Elisa Cavazza, Rachid Benhida, Stéphane Rocchi, Institut de Chimie de Nice (ICN), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine), CHU de Nice, Hôpital Archet 2, Service de Dermatologie, and Hôpital Archet 2 [Nice] (CHU)

Subjects
0301 basic medicine, Programmed cell death, Context (language use), Antineoplastic Agents, Pharmacology, 03 medical and health sciences, Mice, Structure-Activity Relationship, 0302 clinical medicine, In vivo, Pancreatic cancer, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Discovery, Acetamides, medicine, [CHIM]Chemical Sciences, Structure–activity relationship, Animals, Humans, Melanoma, Chemistry, Myeloid leukemia, Cancer, medicine.disease, 3. Good health, Pancreatic Neoplasms, Leukemia, Thiazoles, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Molecular Medicine, Drug Screening Assays, Antitumor
Abstract

International audience; Cancer is the second cause of deaths worldwide and is forecasted to affect more that 22 million people in 2020. Despite dramatic improvement in its care over the last two decades, the treatment of resistant forms of cancer is still an unmet challenge. Thus, innovative and efficient treatments are still needed. In this context, we report herein the synthesis and the evaluation of a new class of bioactive molecules belonging to the N-(4-(3-aminophenyl(thiazol-2-yl)acetamide family. Structure–activity relationships could be driven and resulted in the discovery of lead compound 6b. The latter display high in vitro potency against both sensitive and resistant cancer cell lines on three models: melanoma, pancreatic cancer, and chronic myeloid leukemia (CML). 6b leads to cell death by concomitant induction of apoptosis and autophagy, shows good pharmacokinetic properties, and demonstrates a significant reduction of tumor growth in vivo on A375 xenograft model in mice.

Published
2016
Full Text
View/download PDF

5. Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance

Author

Emilie Jaune, Hella Amdouni, Anne-Sophie Dabert-Gay, Jean-Sébastien Annicotte, Magali Plaisant, Solange Moréra, Delphine Debayle, Corine Bertolotto, Patricia Abbe, Thierry Passeron, Abdelali Lehraiki, Laurent Héliot, Robert Ballotti, Philippe Gual, Baharia Mograbi, Cyril Ronco, Mariano Gonzalez-Pisfil, Thomas Botton, Damien Alcor, Caroline Robert, Michael Cerezo, Stéphane Rocchi, Nabil Rabhi, Véronique Hofman, Armelle Vigouroux, Antoine Millet, Rachid Benhida, Maruf M.U. Ali, Paul Hofman, Florian Rouaud, Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA), Centre méditerranéen de médecine moléculaire (C3M), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institutions et Dynamiques Historiques de l'Économie et de la Société (IDHES), École normale supérieure - Cachan (ENS Cachan)-Université Panthéon-Sorbonne (UP1)-Université Paris 8 Vincennes-Saint-Denis (UP8)-Université Paris Nanterre (UPN)-Centre National de la Recherche Scientifique (CNRS)-Université d'Évry-Val-d'Essonne (UEVE), Institut de Chimie de Nice (ICN), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Nice Sophia Antipolis (... - 2019) (UNS), Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Génomique Intégrative et Modélisation des Maladies Métaboliques (EGID), Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 (PhLAM), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Institut Français de Recherche pour l'Exploitation de la Mer - Brest (IFREMER), Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Microbiologie et enzymologie structurale (MESB3S), Département Biochimie, Biophysique et Biologie Structurale (B3S), Institut de Biologie Intégrative de la Cellule (I2BC), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay-Institut de Biologie Intégrative de la Cellule (I2BC), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay-Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Saclay, Laboratoire d'Enzymologie et Biochimie Structurales, Centre National de la Recherche Scientifique (CNRS), University of Stavanger, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre méditérannéen de médecine moléculaire ( C3M ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Nice Sophia Antipolis - Faculté de Médecine ( UNS UFR Médecine ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ), Institut de Chimie de Nice ( ICN ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Hôpital Archet 2 [Nice] ( CHU ), Institut de Recherche sur le Cancer et le Vieillissement ( IRCAN ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Pathologie Clinique et Expérimentale, Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Hôpital pasteur [Colmar]-CHU Nice, Institut de pharmacologie moléculaire et cellulaire ( IPMC ), Génomique Intégrative et Modélisation des Maladies Métaboliques ( EGID ), Institut Pasteur de Lille, Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Université de Lille-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de Physique des Lasers, Atomes et Molécules - UMR 8523 ( PhLAM ), Université de Lille-Centre National de la Recherche Scientifique ( CNRS ), Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy ( IGR ), Microbiologie et enzymologie structurale ( MESB3S ), Département Biochimie, Biophysique et Biologie Structurale ( B3S ), Institut de Biologie Intégrative de la Cellule ( I2BC ), Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut de Biologie Intégrative de la Cellule ( I2BC ), Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Sud - Paris 11 ( UP11 ) -Université Paris-Saclay-Centre National de la Recherche Scientifique ( CNRS ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Sud - Paris 11 ( UP11 ), Department of Life Sciences, Imperial College London, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris 8 Vincennes-Saint-Denis (UP8)-Université Paris Nanterre (UPN)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS)-Ecole Normale Supérieure Paris-Saclay (ENS Paris Saclay), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (EGENODIA (GI3M)), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Intégrative de la Cellule (I2BC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Hôpital pasteur [Colmar]-Centre Hospitalier Universitaire de Nice (CHU Nice), Institut Gustave Roussy (IGR), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (GI3M), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), Institut Français de Recherche pour l'Exploitation de la Mer - Brest (IFREMER Centre de Bretagne), Institutions et Dynamiques Historiques de l'Économie et de la Société ( IDHES ), École normale supérieure - Cachan ( ENS Cachan ) -Université Panthéon-Sorbonne ( UP1 ) -Université Paris 8 Vincennes-Saint-Denis ( UP8 ) -Université Paris Nanterre ( UPN ) -Université d'Évry-Val-d'Essonne ( UEVE ) -Centre National de la Recherche Scientifique ( CNRS ), Centre d'Etudes Lasers Intenses et Applications ( CELIA ), Université de Bordeaux ( UB ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Français de Recherche pour l'Exploitation de la Mer - Brest ( IFREMER ), Institut Français de Recherche pour l'Exploitation de la Mer ( IFREMER ), Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), and Houel, Ludivine

Subjects
0301 basic medicine, Proto-Oncogene Proteins B-raf, Cancer Research, Programmed cell death, [SDV]Life Sciences [q-bio], Antineoplastic Agents, Pharmacology, Biology, Transcriptome, 03 medical and health sciences, Mice, 0302 clinical medicine, Cell Line, Tumor, medicine, Animals, Humans, Endoplasmic Reticulum Chaperone BiP, Melanoma, Protein Kinase Inhibitors, neoplasms, Heat-Shock Proteins, 030304 developmental biology, Cell Proliferation, Regulation of gene expression, 0303 health sciences, Sulfonamides, [ SDV ] Life Sciences [q-bio], Autophagy, Cell Biology, medicine.disease, Endoplasmic Reticulum Stress, Xenograft Model Antitumor Assays, [SDV] Life Sciences [q-bio], Gene Expression Regulation, Neoplastic, 030104 developmental biology, Oncology, Cell culture, Apoptosis, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Unfolded protein response, Cancer research
Abstract

International audience; Hepatitis B virus (HBV) is a small DNA virus that replicates by reverse transcription of a terminally redundant RNA, the pregenome. Specific packaging of this transcript into viral capsids is mediated by interaction of the reverse transcriptase, P protein, with the 5'-proximal encapsidation signal epsilon, epsilon-function is correlated with the formation of a hairpin structure containing a bulge and a loop, each consisting of 6 nt. To analyse the importance of primary sequence in these regions, we have combined selection of encapsidation competent individuals from pools of randomized epsilon-sequences in transfected cells with in vitro amplification, thus bypassing the current experimental limitations of the HBV system. While no alterations of the authentic loop sequence were detectable, many different sequences were tolerated in the 3'-part of the bulge. However, at the two 5'-proximal bulge positions the wt sequence was strongly selected for, indicating that for RNA packaging close contacts between protein and the 5'- but not the 3'-part of the bulge are important. Such a bipartite organisation provides a structural basis for the recently demonstrated special role of the 3'-part of the bulge as template for the first nucleotides of (-)-strand DNA in HBV reverse transcription.

Published
2016
Full Text
View/download PDF

6. The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML

Author

Eric Solary, Grégory Michel, Arnaud Jacquel, Patrick Auberger, Sandrine Marchetti, Sandrine Obba, Bernard Robaye, Mohamed-Amine Hamouda, Guillaume Robert, Nathalie Droin, Frederic Luciano, Laurent Boyer, Anja Pfeifer, Marc Foretz, Thomas Cluzeau, Dorothée Selimoglu-Buet, Zoheir Hizir, Benoit Viollet, Diogo Gonçalvès, Michael Cerezo, Stéphane Rocchi, and Laurence Legros

Subjects
Macrophage colony-stimulating factor, Cellular differentiation, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Biology, AMP-Activated Protein Kinases, P2RY6, Models, Biological, Monocytes, Uridine Diphosphate, Cell Line, Tumor, Autophagy, Macrophage, Animals, Humans, Receptor, Molecular Biology, Phospholipase C gamma, Receptors, Purinergic P2, Macrophage Colony-Stimulating Factor, Cell Differentiation, Cell Biology, Basic Research Paper, Cell biology, Enzyme Activation, Mice, Inbred C57BL, Leukemia, Myeloid, Monocyte differentiation, Signal transduction, Signal Transduction
Abstract

Autophagy is induced during differentiation of human monocytes into macrophages that is mediated by CSF1/CSF-1/M-CSF (colony stimulating factor 1 [macrophage]). However, little is known about the molecular mechanisms that link CSF1 receptor engagement to the induction of autophagy. Here we show that the CAMKK2-PRKAA1-ULK1 pathway is required for CSF1-induced autophagy and human monocyte differentiation. We reveal that this pathway links P2RY6 to the induction of autophagy, and we decipher the signaling network that links the CSF1 receptor to P2RY6-mediated autophagy and monocyte differentiation. In addition, we show that the physiological P2RY6 ligand UDP and the specific P2RY6 agonist MRS2693 can restore normal monocyte differentiation through reinduction of autophagy in primary myeloid cells from some but not all chronic myelomonocytic leukemia (CMML) patients. Collectively, our findings highlight an essential role for PRKAA1-mediated autophagy during differentiation of human monocytes and pave the way for future therapeutic interventions for CMML.

Published
2015

7. Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis

Author

Mélanie Tichet, Jean-Claude Chambard, Aude Mallavialle, Jean-Philippe Lacour, Michael Cerezo, Jean-François Michiels, Jean-Paul Borg, Stéphane Audebert, Sophie Tartare-Deckert, Nina Fenouille, Damien Ambrosetti, F. Boukari, Marcel Deckert, Maryline Allegra, Virginie Prod'homme, Stéphane Rocchi, Damien Giacchero, Mickaël Ohanna, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), chu de nice, Hôpital Pasteur, Laboratoire Central d’Anatomo Pathologie, Hôpital Pasteur [Nice] (CHU), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU de Nice, Hôpital Archet 2, Service de Dermatologie, Hôpital Archet 2 [Nice] (CHU), Institut de Biologie Valrose (IBV), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), INSERM, Fondation ARC et Fondation de France, ANR-11-LABX-0028,SIGNALIFE,Réseau d'Innovation sur les Voies de Signalisation en Sciences de la Vie(2011), Prod'homme, Virginie, Centres d'excellences - Réseau d'Innovation sur les Voies de Signalisation en Sciences de la Vie - - SIGNALIFE2011 - ANR-11-LABX-0028 - LABX - VALID, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)

Subjects
Lung Neoplasms, Endothelium, MAP Kinase Signaling System, [SDV]Life Sciences [q-bio], Mice, Nude, Vascular Cell Adhesion Molecule-1, General Physics and Astronomy, Vascular permeability, General Biochemistry, Genetics and Molecular Biology, Metastasis, Capillary Permeability, Cell Line, Tumor, Paracrine Communication, Human Umbilical Vein Endothelial Cells, medicine, Animals, Humans, Osteonectin, Neoplasm Metastasis, Melanoma, Multidisciplinary, business.industry, Matricellular protein, Cancer, General Chemistry, medicine.disease, Extravasation, 3. Good health, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, Case-Control Studies, Cancer cell, Immunology, Cancer research, Female, Endothelium, Vascular, business
Abstract

International audience; Disruption of the endothelial barrier by tumour-derived secreted factors is a critical step in cancer cell extravasation and metastasis. Here, by comparative proteomic analysis of melanoma secretomes, we identify the matricellular protein SPARC as a novel tumour-derived vascular permeability factor. SPARC deficiency abrogates tumour-initiated permeability of lung capillaries and prevents extravasation, whereas SPARC overexpression enhances vascular leakiness, extravasation and lung metastasis. SPARC-induced paracellular permeability is dependent on the endothelial VCAM1 receptor and p38 MAPK signalling. Blocking VCAM1 impedes melanoma-induced endothelial permeability and extravasation. The clinical relevance of our findings is highlighted by high levels of SPARC detected in tumour from human pulmonary melanoma lesions. Our study establishes tumour-produced SPARC and VCAM1 as regulators of cancer extravasation, revealing a novel targetable interaction for prevention of metastasis.

Published
2015
Full Text
View/download PDF

8. Is it time to test biguanide metformin in the treatment of melanoma?

Author

Robert Ballotti, Tijana Tomic, Michael Cerezo, and Stéphane Rocchi

Subjects
Drug, Skin Neoplasms, endocrine system diseases, medicine.drug_class, media_common.quotation_subject, Antineoplastic Agents, Dermatology, Pharmacology, Hypoglycemia, Models, Biological, General Biochemistry, Genetics and Molecular Biology, AMP-activated protein kinase, medicine, Humans, Melanoma, media_common, biology, Biguanide, Cell growth, business.industry, Autophagy, nutritional and metabolic diseases, medicine.disease, Metformin, Oncology, biology.protein, business, medicine.drug, Signal Transduction
Abstract

Summary Metformin is the most widely used antidiabetic drug that belongs to the biguanide class. It is very well tolerated and has the major clinical advantage of not inducing hypoglycemia. Metformin decreases hepatic glucose production via a mechanism requiring liver kinase B1, which controls the metabolic checkpoint, AMP-activated protein kinase-mammalian target of rapamycin and neoglucogenic genes. The effects of metformin on this pathway results in reduced protein synthesis and cell proliferation. These observations have given the impetus for many investigations on the role of metformin in the regulation of tumor cell proliferation, cell-cycle regulation, apoptosis, and autophagy. Encouraging results from these studies have shown that metformin could potentially be used as an efficient anticancer drug in various neoplasms such as prostate, breast, lung, pancreas cancers, and melanoma. These findings are strengthened by retrospective epidemiological studies that have found a decrease in cancer risk in diabetic patients treated with metformin. In this review, we have focused our discussion on recent molecular mechanisms of metformin that have been described in various solid tumors in general and in melanoma in particular.

Published
2014

9. Inhibition of melanogenesis by the antidiabetic metformin

Author

Corine Bertolotto, B. Chignon-Sicard, Robert Ballotti, Claire Regazzetti, Michael Cerezo, Florian Rouaud, Abdelali Lehraiki, Stéphane Rocchi, Thierry Passeron, Patricia Abbe, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), and BERTOLOTTO-BALLOTTI, BERTOLOTTO-BALLOTTI

Subjects
Skin Neoplasms, Time Factors, endocrine system diseases, Tyrosinase, Biopsy, Human skin, Skin Pigmentation, Pharmacology, Biochemistry, Melanin, Mice, 0302 clinical medicine, Cyclic AMP, Melanoma, Cells, Cultured, Skin, 0303 health sciences, digestive, oral, and skin physiology, Metformin, 3. Good health, 030220 oncology & carcinogenesis, Melanocytes, medicine.symptom, medicine.drug, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, In Vitro Techniques, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Cell Line, Tumor, medicine, Animals, Humans, Hypoglycemic Agents, Molecular Biology, 030304 developmental biology, Cell Proliferation, Melanins, Microphthalmia-Associated Transcription Factor, Dose-Response Relationship, Drug, business.industry, AMPK, nutritional and metabolic diseases, Cell Biology, medicine.disease, Hyperpigmentation, Mice, Inbred C57BL, Endocrinology, business, Dopachrome tautomerase
Abstract

International audience; Several reports have demonstrated the inhibitory effect of metformin, a widely used drug in the treatment of type 2 diabetes, on the proliferation of many cancers including melanoma. Recently, it has been shown that metformin is able to modulate the cAMP level in the liver. As cAMP has a crucial role in melanin synthesis and skin pigmentation, we investigated the effect of metformin on melanogenesis both in vitro and in vivo. We showed that metformin led to reduced melanin content in melanoma cells and in normal human melanocytes by decreasing cAMP accumulation and cAMP-responsive element-binding protein phosphorylation. This inhibitory effect is correlated with decreased expression of master genes of melanogenesis, microphthalmia-associated transcription factor, tyrosinase, dopachrome tautomerase, and tyrosinase-related protein 1. Furthermore, we demonstrated that the antimelanogenic effect of metformin is independent of the AMPK pathway. Interestingly, topical application of metformin induced tail whitening in mice. Finally, we confirmed the antimelanogenic effect of metformin on reconstituted human epidermis and on human skin biopsies. These data emphasize the depigmenting effect of metformin and suggest a clinical strategy for using metformin in the topical treatment of hyperpigmentation disorders.

Published
2014
Full Text
View/download PDF

10. Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability

Author

Sandy Giuliano, Marius Ilie, Corinne Bertolotto, Florence Pedeutour, Georges F. Carle, Patrick Brest, Paul Hofman, Sophie Barale, Amine Belaid, Michael Cerezo, Elisabeth Corcelle-Termeau, Baharia Mograbi, Valérie Vouret-Craviari, Michel Tauc, Daniel J. Klionsky, Isabelle Rubera, Abderrahman Chargui, Infection bactérienne, inflammation, et carcinogenèse digestive, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Transport Ionique Aspects Normaux et Pathologiques (TIANP), CNRS, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Génétique, physiopathologie et ingénierie du tissu osseux (GéPITOS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Mécanismes biologiques des Altérations du Tissu Osseux (MATOs), UMR E4320 (TIRO-MATOs), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratoire de Pathologie Clinique et Expérimentale, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Hôpital pasteur [Colmar]-Centre Hospitalier Universitaire de Nice (CHU Nice), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA), and Carle, Georges

Subjects
Autophagosome, Cancer Research, Vacuolar Proton-Translocating ATPases, RHOA, Lung Neoplasms, ATG5, Cell, Biology, Giant Cells, Article, Genomic Instability, Cell Line, Small hairpin RNA, 03 medical and health sciences, Mice, 0302 clinical medicine, Cell Line, Tumor, Phagosomes, medicine, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Autophagy, Animals, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, 030304 developmental biology, Cytokinesis, 0303 health sciences, Carcinoma, Cell Membrane, 3. Good health, Cell biology, Midbody, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Proteolysis, biology.protein, Lysosomes, rhoA GTP-Binding Protein
Abstract

Degradation of signaling proteins is one of the most powerful tumor-suppressive mechanisms by which a cell can control its own growth. Here, we identify RHOA as the molecular target by which autophagy maintains genomic stability. Specifically, inhibition of autophagosome degradation by the loss of the v-ATPase a3 (TCIRG1) subunit is sufficient to induce aneuploidy. Underlying this phenotype, active RHOA is sequestered via p62 (SQSTM1) within autolysosomes and fails to localize to the plasma membrane or to the spindle midbody. Conversely, inhibition of autophagosome formation by ATG5 shRNA dramatically increases localization of active RHOA at the midbody, followed by diffusion to the flanking zones. As a result, all of the approaches we examined that compromise autophagy (irrespective of the defect: autophagosome formation, sequestration, or degradation) drive cytokinesis failure, multinucleation, and aneuploidy, processes that directly have an impact upon cancer progression. Consistently, we report a positive correlation between autophagy defects and the higher expression of RHOA in human lung carcinoma. We therefore propose that autophagy may act, in part, as a safeguard mechanism that degrades and thereby maintains the appropriate level of active RHOA at the midbody for faithful completion of cytokinesis and genome inheritance. Cancer Res; 73(14); 4311–22. ©2013 AACR.

Published
2013
Full Text
View/download PDF

11. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms

Author

Tomic T, Pierre Gounon, Sophie Tartare-Deckert, Alexandre Puissant, Philippe Bahadoran, Corine Bertolotto, Patrick Auberger, Frederic Luciano, Michael Cerezo, Maryline Allegra, Stéphane Rocchi, Thomas Botton, Guillaume Robert, Bereder Jm, and Robert Ballotti

Subjects
Cancer Research, medicine.medical_specialty, autophagy, Cell cycle checkpoint, endocrine system diseases, Immunology, ATG5, Transplantation, Heterologous, Mice, Nude, Antineoplastic Agents, Biology, Resting Phase, Cell Cycle, Autophagy-Related Protein 5, Cellular and Molecular Neuroscience, Mice, Internal medicine, Cell Line, Tumor, medicine, melanoma, Animals, Humans, RNA, Small Interfering, Melanoma, Autophagy, digestive, oral, and skin physiology, G1 Phase, apoptosis, nutritional and metabolic diseases, Membrane Proteins, Cell Biology, Cell cycle, medicine.disease, Metformin, Transplantation, Endocrinology, Apoptosis, Cancer research, Beclin-1, RNA Interference, Original Article, Apoptosis Regulatory Proteins, Microtubule-Associated Proteins, medicine.drug
Abstract

Metformin is the most widely used antidiabetic drug because of its proven efficacy and limited secondary effects. Interestingly, recent studies have reported that metformin can block the growth of different tumor types. Here, we show that metformin exerts antiproliferative effects on melanoma cells, whereas normal human melanocytes are resistant to these metformin-induced effects. To better understand the basis of this antiproliferative effect of metformin in melanoma, we characterized the sequence of events underlying metformin action. We showed that 24 h metformin treatment induced a cell cycle arrest in G0/G1 phases, while after 72 h, melanoma cells underwent autophagy as demonstrated by electron microscopy, immunochemistry, and by quantification of the autolysosome-associated LC3 and Beclin1 proteins. In addition, 96 h post metformin treatment we observed robust apoptosis of melanoma cells. Interestingly, inhibition of autophagy by knocking down LC3 or ATG5 decreased the extent of apoptosis, and suppressed the antiproliferative effect of metformin on melanoma cells, suggesting that apoptosis is a consequence of autophagy. The relevance of these observations were confirmed in vivo, as we showed that metformin treatment impaired the melanoma tumor growth in mice, and induced autophagy and apoptosis markers. Taken together, our data suggest that metformin has an important impact on melanoma growth, and may therefore be beneficial in patients with melanoma.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results